EUDA (35) BMGL (53) PIII (24) DCGO (41) ⌘ Pro Terminal →

ALPS Group Inc Ordinary Share (ALPS) — RQD Stock Rating Cockpit

Q: Should I buy, hold, or sell ALPS stock right now?

ALPS Group Inc Ordinary Share (ALPS) currently earns a Roarable Rating of D (Sell — SELL) with 50/100 RQD Confidence. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

Q: What is ALPS's 12-month price target and RQD AI Jury consensus?

ALPS's 12-month base price target is $0.32 (range $0.25 to $3.04), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

$0.33 +0.03% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.33

ALPS Group Inc Ordinary Share (ALPS) carries a Roarable Rating of D (Sell) with 50/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 50/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.4% avg 90D alpha vs SPY) →

ROARABLE D • SELL / AVOID Cap $54.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ALPS Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ALPS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, ALPS Group Inc Ordinary Share (NASDAQ: ALPS) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $0.33 (+0.03% 1D, market cap $54.1M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, ALPS ranks #300 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ALPS compare to EUDA and BMGL in the Health Care sector?

▼

Within the Health Care sector (Medical/Nursing Services), ALPS carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, EUDA (EUDA Health Holdings Limited) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $46.4M) and BMGL (Basel Medical Group Ltd) posts a D+ grade (53/100 RQD, P/E N/A, ROIC —, cap $36.0M). Among the 5-stock peer group, ALPS leads on earnings multiple (N/A) while EUDA leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ALPS?

▼

For ALPS Group Inc Ordinary Share (ALPS), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #300 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.33 (-0.18%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 50/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.4% avg 90D alpha vs SPY • 49.3% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ALPS)Realized 20D OHLCV Swing Band: ±8.7%

Deterministic 5-Pillar Attribution (50/100 Composite)

🔍 WHY ALPS SCORES 50/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (24% of score)

SEC XBRL Trailing 12 Months: 0% FCF Margin ($1.5M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Macro Regime Fit8/20 pts (-12 pt drag)

Macro rate sensitivity & RSI-14 (27.4) create a -12 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$0.35-2.9% Next Q

Q2 (-2Q)

Grade C$0.34-2.9% Next Q

Q3 (-1Q)

Grade C-$0.33+0% Next Q

Current

Grade D$0.33-1.4% Hist 90D α

Trajectory: C (58) → D (50)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ALPS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ALPS currently carries a cautious 50/100 (D) rating due to Macro Regime Fit (8/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.37) and Max Pain ($0.35) forces dealer call-delta covering toward $3.04.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ALPS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ALPS Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 50%NO 50%Trade / Inspect Odds →

RSI-14 MOMENTUMOVERSOLD (<32)

27.430 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE4% OF RANGE

L: $0$0.33H: $3

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 17 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D+RQD 21 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on ALPS

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

NEUTRAL (60)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (42)

17/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like ALPS

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ALPS)

✓Walkthrough of ALPS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ALPS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -64.13%⚡ TESTING RESISTANCE

2026-11-02O $0.32H $0.33L $0.32C $0.33VOL 28.8K

RES: $0.39SUP: $0.32SMA50: $0.37SMA200: $0.68

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ALPS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ALPS Butterfly Map → + Track ALPS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ALPS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ALPS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ALPS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ALPS)

Health Care Rank #300 of 1016 ⚔️ EUDA vs ALPS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ALPS vs. EUDA, BMGL, PIII, DCGO)

Industry: Medical/Nursing Services (29 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, ALPS Group Inc Ordinary Share (ALPS) ranks #300 by composite RQD confidence (50/100, grade D) and #739 by equity capitalization ($54.1M). Within this direct 5-issuer industry benchmark cohort, ALPS leads on earnings valuation at N/A trailing P/E, while EUDA leads on capital efficiency and profitability with -35.0% ROIC and 43.9% gross margin. BMGL currently holds the highest overall quantitative score in the immediate peer group at 53/100 (D+) compared with ALPS at 50/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ALPS ACTIVE ALPS Group Inc Ordinary Share	D	50/100	—	—	—	+0.03%	$54.1M	Benchmark Subject
EUDA EUDA Health Holdings Limited	D-	35/100	—	43.9%	-35.0%	+14.19%	$46.4M	/euda-vs-alps →
BMGL Basel Medical Group Ltd	D+	53/100	—	—	—	+6.11%	$36.0M	/bmgl-vs-alps →
PIII P3 Health Partners Inc. (Class A)	E	24/100	—	—	-35.0%	-4.05%	$30.5M	/piii-vs-alps →
DCGO DocGo Inc.	D-	41/100	—	—	-35.0%	-9.59%	$27.0M	/dcgo-vs-alps →

2. ALPS Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

ALPS Group Inc Ordinary Share (ALPS) operates in Medical/Nursing Services (Health Care) with an equity capitalization of $54.1M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. ALPS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ALPS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ALPS compare to EUDA and BMGL in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ALPS?

Where is ALPS trading relative to its 50-day, 200-day, and 52-week technical levels?

ALPS last traded at $0.33 (+0.03% on volume of 36,187 shares), positioning the stock -10.81% below its 50-day simple moving average ($0.37) and -51.47% below its 200-day simple moving average ($0.68). Across its 52-week range of $0.23 to $2.90, ALPS sits at the 3.7% percentile with a 14-day RSI of 27.4 (OVERSOLD (<32)) and an implied next-earnings move of ±8.7% ($1.00 to $0.36).

ALPS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell ALPS stock right now?

ALPS Group Inc Ordinary Share (ALPS) currently earns a Roarable Rating of D (Sell — SELL) with 50/100 RQD Confidence. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

What is ALPS's 12-month price target and RQD AI Jury consensus?

ALPS's 12-month base price target is $0.32 (range $0.25 to $3.04), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: ALPS RQD Cockpit ALPS 12M Forecast ALPS Earnings & Move ALPS Dividends & DRIP ALPS Insiders & 13F ALPS Whale Options ALPS Profit Sankey ALPS News & Why

ROARABLE RATING BRIEF • RQD 50/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ALPS — ALPS Group Inc Ordinary Share: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T14:19:11Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, ALPS scores 50 out of 100, grade D, labeled "Roarable Sell — Underperform / Distribution Warning." The five pillars are: Fundamental Cash Engine 12/20 (ROIC 0%; FCF yield 0%); Whale 13F Flow 8/20 (institutional accumulation and options positioning); Insider Conviction 9/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit 8/20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet 13/20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5).

For a prospective investor, the cash-engine pillar is the weakest signal in the source data: a reported 0% ROIC and 0% FCF yield mean the rating does not credit the business with generating returns on capital or free cash flow. The forensic pillar is comparatively stronger, with an Altman Z of 2.5 and a Piotroski F of 6/9 cited in the rating, but these are balance-sheet and accounting-quality indicators rather than evidence of earnings power. Flow and insider pillars score modestly, indicating limited sponsorship signals in the rating inputs. The overall verdict points to distribution-warning conditions rather than an upside-driver profile. Valuation tradeoffs cannot be evaluated against earnings, since P/E and EPS are not available in source data.

Open Questions

What are the company's revenue, operating income, and net income for any reported period?
What does ALPS sell, and to which customers, and how does it generate revenue?
Why are ROIC and FCF yield reported at 0%, and is the company currently profitable or cash-generative?
What drove the stock's move from a 52-week high of $2.9 to $0.32 and what explains the $0.23 low?
Who are the institutional holders, insiders, and analysts covering the stock?

ALPS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for ALPS Group Inc Ordinary Share (ALPS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ALPS Debate Forum (3) ↓

🟢 CATALYST Yahoo • 3d ago

Alps Group Inc Announces Shareholder Approval for a Share Consolidation, Share Capital Increase, and Adoption of Second Amended and Restated Memorandum and Articles of Association

KUALA LUMPUR, Malaysia, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (“Alps” or “the Company”) (Nasdaq: ALPS), an integrated biotechnology platform headquartered in Malaysia, today announced that its shareholders app

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 3d ago

Alps Group Shareholders Approve 1-For-5 Share Consolidation And Capital Increase

Alps Group Inc ("Alps" or "the Company") (NASDAQ:ALPS), an integrated biotechnology platform headquartered in Malaysia, today announced that its shareholders approved, in accordance with Cayman Islands

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 87d ago

Alps Group Inc Reports Fiscal Year 2026 Financial Results and Provides Business Update

Revenue Grew 44% to $4.9 Million, Led by Continued Growth Across Cellular Therapy, Medical Testing, Laboratory and Aesthetics Beauty Services, and Healthcare Products Began Trading on the Nasdaq Global Market Under the T

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 132d ago

Alps Group Inc Launches Patient-Derived Organoid Program to Advance Personalized Cancer Care in Southeast Asia

Agreement Marks Company’s Expansion into Precision Oncology Testing, with the Goal of Establishing Malaysia's First Clinically Validated PDO PlatformKUALA LUMPUR, Malaysia, June 23, 2026 (GLOBE NEWSWIRE) -- Alps Group In

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 146d ago

Alps Group Inc Expands MyGenome Accreditation to Include Whole Genome Sequencing Under MS ISO 15189:2022

MyGenome Joins a Limited Number of Southeast Asian Laboratories Delivering WGS Under Internationally Recognized Clinical Standards, Strengthening its Position in Southeast Asian GenomicsKUALA LUMPUR, Malaysia, June 09, 2

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 167d ago

Alps Group Inc Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

KUALA LUMPUR, Malaysia, May 19, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated biotechnology research and health

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 199d ago

Alps Group Appoints Former Ernst & Young Partner to Board of Directors, Strengthening Governance and Capital Markets Oversight

KUALA LUMPUR, Malaysia, April 17, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a biotechnology research and healthcare platform f

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 252d ago

Alps Group Inc Publishes Clinical Safety, Tolerability and Effectiveness Data Supporting Advancement of Its Autologous NK Cell Pipeline Using an In-House Developed Culture Protocol

KUALA LUMPUR, Malaysia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated biotechnology research and healt

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ALPS Bull vs. Bear Conversation Board — What's Your Call at $0.33?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ALPS 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $0.35 (+9.4%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ALPS (D • RQD 50/100) a Buy at $0.32?

Welcome to the ALPS (ALPS Group Inc Ordinary Share) Roar Pit. Current RQD Composite is 50/100 (Roarable Sell — Underperform / Distribution Warning) in Medical/Nursing Services. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.26 (-18.8%)

Spot @ $0.32

Pump the brakes on ALPS — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ALPS, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless ALPS Group Inc Ordinary Share expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

QU QuantViper Verified K Arena Trader 🐂 BULLISH 🎯 Target: $0.41 (+28.1%)

Spot @ $0.32

ALPS cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ALPS, the market is fixating on short-term headline noise in Medical/Nursing Services and ignoring the balance sheet and cash flow trajectory. At $0.32 (52-wk range $0.23 - $2.90), any beat on forward guidance forces shorts and underweight funds to chase.